Sleep is increased by liraglutide, a glucagon-like peptide-1 receptor agonist, in rats
- PMID: 36410565
- DOI: 10.1016/j.brainresbull.2022.11.012
Sleep is increased by liraglutide, a glucagon-like peptide-1 receptor agonist, in rats
Abstract
Introduction: Sleep disturbances are prominent in drug use disorders, including those involving opioids in both humans and animals. Recent studies have shown that administration of liraglutide, a glucagon-like peptide-1 agonist, significantly reduces heroin taking and seeking in rats. In an effort to further understand the action of this substance on physiological functions and to evaluate safety issues for its potential clinical use, the aim of the present study was to determine whether the dose of liraglutide found effective in reducing responding for an opioid also could improve sleep in drug-naïve rats.
Methods: Using a within-subjects design, adult male rats chronically implanted with EEG and EMG electrodes received subcutaneous injection of saline or 0.06, 0.10, 0.30 or 0.60 mg/kg liraglutide. The 0.10 and 0.30 mg/kg doses are known to be most effective in reducing responding for heroin in rats at light or dark onset during a 12:12 h light-dark cycle (0.10 mg/kg for taking and seeking, 0.30 mg/kg for seeking). EEG and EMG were recorded across the 24 h period following each injection.
Results: After both dark and light onset injections, liraglutide dose-dependently decreased wakefulness and increased non-rapid eye movement (NREM) sleep except at the lowest dose. The bout length of wakefulness and NREM sleep were decreased and increased, respectively. Whether administered at light or dark onset, the above alterations occurred primarily during the dark period (i.e., during the active period). The animals' body weight was decreased after liraglutide treatments as expected since it is clinically used for the treatment of obesity.
Conclusion: These data indicate that liraglutide, at doses known to reduce responding for heroin and fentanyl, also increases NREM sleep, suggesting that the increase in sleep may contribute to the protective effects of liraglutide and may promote overall general health.
Keywords: Addiction; EEG Slow Wave Activity; Glucagon-like peptide-1; Liraglutide; Sleep.
Copyright © 2022. Published by Elsevier Inc.
Conflict of interest statement
Conflict of interest J. Fang is the creator of SleepMaster™ and SleepAnalysis™ programs, and is the owner of both computer programs and Biosoft Studio. P.S. Grigson and P. Miller have no conflict of interest in this research.
Similar articles
-
Dose titration with the glucagon-like peptide-1 agonist, liraglutide, reduces cue- and drug-induced heroin seeking in high drug-taking rats.Brain Res Bull. 2022 Oct 15;189:163-173. doi: 10.1016/j.brainresbull.2022.08.022. Epub 2022 Aug 28. Brain Res Bull. 2022. PMID: 36038016 Free PMC article. Review.
-
Acute treatment with the glucagon-like peptide-1 receptor agonist, liraglutide, reduces cue- and drug-induced fentanyl seeking in rats.Brain Res Bull. 2022 Oct 15;189:155-162. doi: 10.1016/j.brainresbull.2022.08.023. Epub 2022 Aug 27. Brain Res Bull. 2022. PMID: 36031011 Review.
-
Glucagon-like peptide-1 receptor agonist, liraglutide, reduces heroin self-administration and drug-induced reinstatement of heroin-seeking behaviour in rats.Addict Biol. 2022 Mar;27(2):e13117. doi: 10.1111/adb.13117. Epub 2021 Nov 21. Addict Biol. 2022. PMID: 34802173 Free PMC article.
-
Acute glucagon-like peptide-1 receptor agonist liraglutide prevents cue-, stress-, and drug-induced heroin-seeking in rats.Behav Pharmacol. 2022 Aug 1;33(5):364-378. doi: 10.1097/FBP.0000000000000685. Epub 2022 Jun 7. Behav Pharmacol. 2022. PMID: 35695511 Free PMC article.
-
Neuropeptide-Y Y2-receptor agonist, PYY3-36 promotes non-rapid eye movement sleep in rat.Neurosci Res. 2006 Mar;54(3):165-70. doi: 10.1016/j.neures.2005.11.006. Epub 2005 Dec 27. Neurosci Res. 2006. PMID: 16378653
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources